Spyre Therapeutics director reports option exercise, share sales

Spyre Therapeutics, Inc. director Jeffrey W. Albers reported an option exercise and related share sales on August 7, 2026.

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. director Jeffrey W. Albers reported an option exercise and related share sales on August 7, 2026. He exercised stock options covering 5,000 shares of common stock at a $10.39 exercise price and retained options on 45,000 shares. On the same date, he reported sales totaling 23,000 shares of common stock at weighted average prices slightly above $104 per share, including sales by Sessions LLC reported as indirect ownership. All transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Albers Jeffrey W.

Role Director

Sold 23,000 shs ($2.40M)

Approx. gross sale proceeds $2.40M

Approx. exercise cost $52K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F5	5,000	$0.00	$0.00
Exercise	Common Stock F1	5,000	$10.39	$52K
Sale	Common Stock F1, F2	5,000	$104.47	$522K
Sale	Common Stock F1, F3	8,000	$104.38	$835K
Sale	Common Stock F1, F4	10,000	$104.68	$1.05M

Holdings After Transaction: Stock Option (Right to Buy) — 45,000 contracts (Direct); Common Stock — 0 shares (Direct); Common Stock — 9,360 shares (Indirect, By Sessions LLC)

Footnotes (5)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
2. F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
4. F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
5. F5. This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Key Figures

Options exercised: 5,000 shares Exercise price: $10.39 per share Shares sold (total): 23,000 shares +4 more

7 metrics

Options exercised 5,000 shares Stock option for common stock exercised on August 7, 2026

Exercise price $10.39 per share Exercise price of stock option covering 5,000 shares

Shares sold (total) 23,000 shares Common stock sales on August 7, 2026, direct and indirect

Direct sale price $104.47 per share Weighted average price for 5,000 directly held shares sold

Indirect sale prices $104.38 and $104.68 per share Weighted average prices for 8,000 and 10,000 shares sold by Sessions LLC

Options remaining 45,000 shares Stock option shares remaining after 5,000-share exercise

10b5-1 plan adoption date April 16, 2026 Date of Rule 10b5-1 trading plan governing these transactions

Key Terms

Rule 10b5-1 trading plan, weighted average price, indirect, Stock Option (Right to Buy), +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported above is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirect financial

"ownership_type": "indirect","ownership_code": "I""

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

vest and become exercisable financial

"shares of the Issuer's common stock, which vest and become exercisable in 36 equal"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SYRE director Jeffrey W. Albers report in this Form 4?

Jeffrey W. Albers reported exercising stock options for 5,000 shares of Spyre Therapeutics common stock and selling 23,000 shares, including indirect sales through Sessions LLC, all dated August 7, 2026 under a trading plan.

How many Spyre Therapeutics (SYRE) shares did Albers sell on August 7, 2026?

Albers reported total sales of 23,000 shares of Spyre Therapeutics common stock, combining 5,000 shares held directly and 18,000 shares held indirectly through Sessions LLC, executed at weighted average prices around $104 per share.

What option exercise did Albers disclose for Spyre Therapeutics (SYRE)?

He disclosed exercising a stock option for 5,000 shares of Spyre Therapeutics common stock at an exercise price of $10.39 per share, leaving 45,000 option shares remaining exercisable under the same option grant.

Were the SYRE share transactions by Albers under a Rule 10b5-1 plan?

Yes. The filing states the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026, indicating they followed a pre-arranged trading schedule rather than discretionary same-day decisions.

What prices were reported for Albers’ SYRE share sales?

The reported weighted average prices were $104.47, $104.38 and $104.68 per share. Footnotes explain each figure reflects multiple transactions within price ranges from about $103.52 to $106.01, with full breakdowns available on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/10/2026 - 09:31 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Albers Jeffrey W.

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2026		M(1)		5,000	A	$10.39	5,000	D
Common Stock	08/07/2026		S(1)		5,000	D	$104.47(2)	0	D
Common Stock	08/07/2026		S(1)		8,000	D	$104.38(3)	19,360	I	By Sessions LLC
Common Stock	08/07/2026		S(1)		10,000	D	$104.68(4)	9,360	I	By Sessions LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.39	08/07/2026		M(1)			5,000	(5)	11/22/2033	Common Stock	5,000	$0	45,000	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

5. This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	08/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)